@18KHarmoni. Awak memang cerdik.
Sekadar pandai sebut Kanger con company.

Orang gila belakang rumah saya pun pandai sebut. He He

@18KHarmoni.
Which info is not true. Forward it here so all of us can see that the info is NOT TRUE.

-------------------
1. Article 1: https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-05-29-story-h1565953920-Kanger_017_The_Bamboo_Flooring_And_Related_Products_Company_Is_Trying_H.jsp

REMARK: Let us read my conclusion.

Therefore, we are hoping that, sooner Kanger will be successful in securing their objective to be an approved Covid-19 vaccines distributor in Malaysia.

2. Article 2: https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-06-02-story-h1566015706-Is_It_True_That_The_Process_of_Registering_The_Sinopharm_Vaccine_With_N.jsp

REMARK: Let us read my conclusion.

The Sinopharm / BIBP1 vaccine has been approved by WHO, whereas the Sinopharm / WIBP1 is still under its assessment process by WHO. Therefore, it’s better for Kanger to focus more on the currently approved vaccine by WHO, which is Sinopharm / BIBP1 for NPRA's approval. We, the investors of Kanger hope to receive some good news on its approval soon.

3. Article 3: https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

REMARKS: This article intended to report the current status of each MOUs and Agreements involving Kanger started from August 2020.

I wrote this article based on my research from www.bursamalaysia.com and information reported on the web. Any misreporting and emission of the information should not be my intention. All the information given is not for buy call or sell call purposes.

@18KHarmoni. Apa yang salah info nya.
Semua info saya ada rujukannya ada report dan linknya.
Saya berpandu kepada info saja.
Kenapa nak marah. Sekadar cari info dan cuba kongsi.
Percaya atau tidak fikir sendiri. TAYOR

Saya memang salesman. Bukan digaji oleh siapa-siapa.
Konsep saya, bila dah beli saham dalam sesuatu saham walaupun sedikit,
saya cuba "sale" kaunter tu jika mampu.

Cari maklumat dan ambil langkah untuk sebarkannya, termasuk buat artikel blog.
Alasan mestilah nak cover kaunter yang kita masuk.

Awak tengok sejarah saya dalam kaunter lain, termasuk Nexgram dan Bornoil.
Saya baru aktif dalam forum sejak tahun lepas sahaja.

Nampaknya betul-betul berpengaruh NPRA1985 sebelum ini.
Lebih baik awak bincang fasal Kanger saja.
Ada ke tak ada NPRA1985 di sini, bukan satu isu.
Teruskan saja usaha awak untuk kutuk Kanger.
Saya pun fikir elok juga kalau dapat harga yang lebih rendah nanti.
5.5 sen ke, 6 sen ke. He He

Nujum Pak Belalang memang pandai. Buat tekaan tanpa bukti pun.
Seperti selalu, naysayer tanpa bukti.

Rugi saya tak dapat bersama NPRA1985 sebelum ini di dalam kaunter ini memandangkan saya amat baharu di sini.

Daripada fikir fasal NPRA1985, lebih baik fikir fasal kaunter ni saja.

Dapatkan maklumat untuk kenal pasti potensi pelaburan di dalam kaunter ini perlu lebih diberi perhatian., tak kiralah sebagai "day trader" ke, spekulator ke atau investor untuk jangka panjang.

Bagi yang berperanan sebagai Naysayer pun ada gunanya, mereka dapat keluarkan isu untuk dijawab oleh pihak lain.

Di mana-mana kaunter pun ada pros dan cons.

Macquarie Bank to invest in Nice Capital Emas. I think due to the diversification of NICE’s existing core business to include exploration of minerals, gold mining (in Kelantan) and mining related business
-----------------
On 14 April 2021, NICE had entered into a subscription agreement with
Macquarie Bank for Macquarie Bank to subscribe for up to 124,000,000
NICE Shares.

On even date, NICE had also entered into a subscription agreement with
Mdm Heah to allot and issue 22,000,000 Placement Shares for a total
consideration of RM4,032,600 or at RM0.1833 per Placement Share.

@18KHarmoni. He He. Saja nak tolong beri pencerahan sikit kepada issue yang dibangkitkan saudara kita . Prospek bisnis semasa kan buuuluuuh. Vaksin tu BONUS.

-------------------
hlh1962 If next QR got revenue and profit then there is hope and not scam like Ikan bilis says. If still like last QR then something is quite wrong somewhere

Prospects for the financial period ending 31 March 2021 (“FPE 2021”)

The Group has identified the following main strategies to continue to grow its businesses:-

(a) Expansion into new bamboo concession and processing plant in Jingzhou, the PRC
which has commenced operations in current financial quarter.

(b) Expansion of the Group’s flooring products with the launching of new series of bamboo
flooring products.

(c) Enhancing the Group’s flooring products to focus more on ‘green’ strand woven
products.

(d) Expansion of the Group’s product portfolio to include bamboo furniture marketed under
the ‘KAR-ACE’ brand.

(e) Expansion into wood flooring products by promoting Classen’s products in the PRC
through the collaboration with Classen GmbH as the Group is the exclusive distributor
for Classen’s products in the PRC.

(f) Expansion of the Group’s presence by increasing the number of appointed dealers in
its sales network and number of sales and marketing channels, for both its own and
third party products.

(g) Identifying candidates to be the Group’s master agents/distributors in countries such
as Malaysia, Australia and New Zealand.

(h) Intensifying efforts in the adoption and building out of a comprehensive omni-channel
marketing strategy which is designed to cover all points of contact with existing and
potential new customers. The Group is also cooperating closely with its dealers in
implementing effective Online-to-Offline marketing and delivery channels. The online
platforms include JD.com, Alibaba’s Taobao and various mini-programs offered by
social media networks like WeChat.

Premised on the above, the Board is cautiously optimistic on the prospects of the Group for
FPE 2021.

@gohkimhock.
You can refer these blog articles to get some ideas about Kanger's efforts and chances to secure this vaccine business:

1. https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-05-29-story-h1565953920-Kanger_017_The_Bamboo_Flooring_And_Related_Products_Company_Is_Trying_H.jsp

2. https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-06-02-story-h1566015706-Is_It_True_That_The_Process_of_Registering_The_Sinopharm_Vaccine_With_N.jsp

@Noobie. He He. Ikan di air sudah nampak jantan betinanya.
Okay lah macam tu.
Terbukti awak masih ada sedikit faith dengan Kanger

@gohkimhock. You can have your own perception.
Your perception not surely true.
We don't know what will happen in the future.
There is a probability, therefore there stands a hope.

Nobody point a gun to make you believe it or not.

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations

7 May 2021 News release Reading time: 3 min (917 words)

WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations

7 May 2021 News release Reading time: 3 min (917 words)

WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).

Procurement of the Covid-19 vaccines is a challenging task for the government.
Needs helps from private sector???

https://www.freemalaysiatoday.com/category/highlight/2021/06/07/ema-warns-against-heparin-for-covid-19-vaccine-clots/

The global capacity to manufacture vaccines remains limited: To cover 70 per cent of the global population, at least 11 billion doses are required. This need simply cannot be met by the manufacturers immediately.

High-income countries have acquired 77 per cent of Pfizer’s, 27 per cent of AstraZeneca’s and 18 per cent of Sinovac’s 2021 COVID-19 vaccine production capacity.

Estimates suggest that with an average of 60,433 doses administered daily, Indonesia would take over 10 years to vaccinate 75 per cent of its population.

The slow progress of COVID-19 vaccination in Indonesia can be put down to limited global vaccine supply, the unpreparedness of the national health system and vaccine hesitancy.

Aiyah....

@greedy44. There is only one project with MOU status from the list. The rest, it's an agreement or contract.

gohkimhock only Pharmaniaga and Duopharma are allowed by the Malaysian govt to deal with vaccine. The others(including ucrest and yongtai) are all just jumping on the bandwagon without proper license and knowledge. You can't even make simple medicine, wanna deal with vaccine?
-------------------------

1. Perjanjian sebagai SOLE DISTRIBUTOR yang dilantik untuk 3 tahun oleh Sinopharm dah ada - SETTLE

Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107

2. MOU untuk wakil distributor bagi pihak Kanger dah ada iaitu Zuellig Pharma - SETTLE

Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154098
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

Nota: Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia. Kanger will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes. The first batch of vaccines is expected to arrive in Malaysia on May 2021).


3. MOU untuk saluran jualan vaksin ke kilinik swasta di Malaysia dah ada iaitu KSport - SETTLE

Sumber:

1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154097
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

SEKARANG TUNGGU UNTUK PROSES APPROVAL OLEH KERAJAAN DAN NPRA SAHAJA.

Artikel blog. Sapa-sapa nak tahu fasal perkembangan MOU dan agreement yang dibuat oleh Kanger boleh rujuk sini.

"The Currents Status of MOUs and Agreements Relating To KANGER (0170)"


https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

2obakh122.
------------------
1. The current Kanger's Bamboo Floring and related product businesses

Kanger (017) is a "green" building materials provider, specialising in the manufacturing and trading of bamboo flooring and related products for the residential and commercial markets under its brands 'Kanger' and 'KAR Masterpiece' as well as OEM at the request of its customers. In additional, it also sell strand woven bamboo planks, a semi-finished product from its strand woven bamboo flooring manufacturing process, to furniture and building materials manufacturers as raw materials for their production. The bamboo flooring and related products business is still running well as can be seen at these websites:

1. https://krbamboo.en.china.cn/

2. https://shenzhenkanger1.sell.everychina.com/

3. https://www.tradewheel.com/co/shenzhen-kanger-bamboo-wood-45509/products/



On September 2020, Kanger planned to strengthen their bamboo products business. Kanger is on target to become the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre, which was developed in collaboration with the local government of Jingzhou, Hunan Province, China. Kanger has accumulated vast experience and strong know-how of the bamboo industry, having been involved in the bamboo processing business over the past 16 years.

(Source: https://www.theborneopost.com/2020/09/10/kanger-aims-to-be-worlds-largest-bamboo-products-producer/)


2 Kanger are in the process of exploring new businesses:

A. To secure as a distributor of Sinopharm Covid-19 vaccines in Malaysia.

B. To be involved in the sales and trading of building materials, which include, timber flooring, tiles, bulk cement, concrete, locksets and sanitary ware by acquiring 51% equity interest in Sung Master.

https://www.theedgemarkets.com/article/malaysia-delivered-357m-covid19-vaccine-shots-so-far

Kelulusan WHO tingkatkan keyakinan terhadap vaksin Sinovac - Khairy (2 Jun 2021)

Kelulusan Pertubuhan Kesihatan Sedunia (WHO) terhadap vaksin COVID-19 Sinovac akan meningkatkan keyakinan terhadap pengambilan vaksin tersebut.

Menurut Menteri Penyelaras Program Imunisasi Covid-19 Kebangsaan (PICK) Khairy Jamaluddin Abu Bakar, ini membuktikan vaksin tersebut selamat dan berkesan.

Sumber: https://www.astroawani.com/berita-malaysia/kelulusan-who-tingkatkan-keyakinan-terhadap-vaksin-sinovac-khairy-301080

Kelulusan WHO tingkatkan keyakinan terhadap vaksin Sinovac - Khairy (2 Jun 2021)

Kelulusan Pertubuhan Kesihatan Sedunia (WHO) terhadap vaksin COVID-19 Sinovac akan meningkatkan keyakinan terhadap pengambilan vaksin tersebut.

Menurut Menteri Penyelaras Program Imunisasi Covid-19 Kebangsaan (PICK) Khairy Jamaluddin Abu Bakar, ini membuktikan vaksin tersebut selamat dan berkesan.

Sumber: https://www.astroawani.com/berita-malaysia/kelulusan-who-tingkatkan-keyakinan-terhadap-vaksin-sinovac-khairy-301080

@IbnuShaari.

For Example;
MY E.G has a NOSH of 3.777 million and @ RM1.96. MY E.G was proposed to add another 4.149 million Bonus Shares via its 1:1 Bonus Share. From the next PP exercise, up to 220 million new share will added. What a big NOSH MY E.G. will has then..

Note: May be we can't compare between "a Scam company" with "a non scam company". He He

@civic. Ya tak ada reduction dalam kuantiti saham dan harga(di sini saya faham melibatkan pengekalan harga par value share)

UPDATED NEWS...

KJ sahkan ada pihak tempatan cuba daftar vaksin Sinopharm

Menteri Penyelaras Program Imunisasi COVID-19 Kebangsaan sahkan terdapat beberapa pihak tempatan yang sedang cuba mendaftarkan vaksin Sinopharm dihasilkan syarikat farmaseutikal dari China. Vaksin sinopharm tidak termasuk di dalam Program Imunisasi COVID-19 Kebangsaan (PICK). Kata Khairy Jamaluddin, perkara berkenaan adalah dibenarkan dan pihaknya mengalu-alukan perkara tersebut. (May 21, 2021)

Sumber: https://www.astroawani.com/video-malaysia/covid-19-kj-sahkan-ada-pihak-tempatan-cuba-daftar-vaksin-sinopharm-1905361

UPDATED NEWS...

KJ sahkan ada pihak tempatan cuba daftar vaksin Sinopharm

Menteri Penyelaras Program Imunisasi COVID-19 Kebangsaan sahkan terdapat beberapa pihak tempatan yang sedang cuba mendaftarkan vaksin Sinopharm dihasilkan syarikat farmaseutikal dari China. Vaksin sinopharm tidak termasuk di dalam Program Imunisasi COVID-19 Kebangsaan (PICK). Kata Khairy Jamaluddin, perkara berkenaan adalah dibenarkan dan pihaknya mengalu-alukan perkara tersebut. (May 21, 2021)

Sumber: https://www.astroawani.com/video-malaysia/covid-19-kj-sahkan-ada-pihak-tempatan-cuba-daftar-vaksin-sinopharm-1905361

KJ sahkan ada pihak tempatan cuba daftar vaksin Sinopharm

Menteri Penyelaras Program Imunisasi COVID-19 Kebangsaan sahkan terdapat beberapa pihak tempatan yang sedang cuba mendaftarkan vaksin Sinopharm dihasilkan syarikat farmaseutikal dari China. Vaksin sinopharm tidak termasuk di dalam Program Imunisasi COVID-19 Kebangsaan (PICK). Kata Khairy Jamaluddin, perkara berkenaan adalah dibenarkan dan pihaknya mengalu-alukan perkara tersebut. (May 21, 2021)

Sumber: https://www.astroawani.com/video-malaysia/covid-19-kj-sahkan-ada-pihak-tempatan-cuba-daftar-vaksin-sinopharm-1905361

@civicfc. Ya. Buktinya kalau ada melibatkan pengurangan share semestinya pegangan kuantiti saham kita telah dikurangkan sekarang kerana capital reduction pun telah diluluskan dalam EGM yang lalu.

@BilisMasin.
Ivermectin telah berjaya mengurangkan 60% kes covid harian di India

-------------------------
Syukur kepada Tuhan. Ianya amat baik untuk manusia keseluruhannya, dan anugerah Tuhan untuk kita semua jika ianya benar.

@satriahijau. Ya

Trust What about Kanger? Does it has a solid distribution agreement for sinopharm vaccine. What is the status of sinopharm vaccine with NRPA. WHO approved it a while back, Ready to go once approved? A better option than YT?

-------------------------------------

Some information on the approval of Sinopharm Covid-19 vaccines and other vaccines by WHO. A theory relating the status of Sinopharm Covid_19 vaccine application with NPRA also can be referred in this article.


Article: Is It True That The Process of Registering The Sinopharm Vaccine (With NPRA) Has Started?

Source: https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-06-02-story-h1566015706-Is_It_True_That_The_Process_of_Registering_The_Sinopharm_Vaccine_With_N.jsp

Sedikit maklumat boleh dirujuk berkaitan kelulusan vaksin Sinopharm di peringkat WHO dan teori berkaitan status permohonan kelulusan NPRA vaksin Sinopharm tersebut yang ada kaitan dengan Kanger.
-------------------------------

Article: Is It True That The Process of Registering The Sinopharm Vaccine (With NPRA) Has Started?

Source: https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-06-02-story-h1566015706-Is_It_True_That_The_Process_of_Registering_The_Sinopharm_Vaccine_With_N.jsp

@Hasli1987. Saya rasa yang dirujuk melibatkan vaksin dikaitkan dengan YongTai. Untuk tujuan trial 3. Di Malaysia juga akan dibuat trial bersama-sama dengan dari beberapa negara lain.
--------------------------------
Kenyataan Akhbar KPK 5 Jun 2021 – Kajian Klinikal Produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated Keluaran Shenzhen Kangtai Biological Products Co., Ltd., China

Kementerian Kesihatan Malaysia (KKM) ingin memaklumkan bahawa terdapat tambahan satu (1) kajian klinikal yang melibatkan vaksin COVID-19 telah diluluskan oleh Bahagian Regulatori Farmasi Negara (NPRA) pada 28 Mei 2021. Kajian klinikal ini melibatkan produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL yang dikilangkan oleh pengilang Shenzhen Kangtai Biological Products Co., Ltd. di negara China.

Kajian Klinikal Fasa 3 ini akan dijalankan di lapan (8) pusat penyelidikan di Malaysia dengan sasaran peserta sebanyak 3,000 orang dewasa yang berumur 18 tahun dan ke atas serta dijangka akan mengambil masa selama 15 hingga 19 bulan. Malaysia merupakan salah sebuah negara yang terlibat dalam kajian klinikal ini selain daripada Colombia, Argentina, Pakistan, Filipina dan Ukraine. Vaksin ini juga telah diluluskan oleh negara China melalui Emergency Use Approval pada 14 Mei 2021.

Tambahnya, setakat ini, terdapat enam produk vaksin Covid-19 yang telah selesai dinilai oleh NPRA dalam masa yang ditetapkan dan telah mendapat kelulusan pendaftaran bersyarat daripada PBKD.

Katanya, pihak NPRA juga sedang menilai BEBERAPA PERMOHONAN BAHARU bersyarat vaksin-vaksin Covid-19 pada masa ini.

“Permohonan ini juga akan disegerakan dengan kaedah yang sama. NPRA sememangnya sentiasa terbuka menerima pandangan pelbagai pihak,” katanya

Source: https://www.kosmo.com.my/2021/05/25/npra-nafi-lewat-lulus-produk-vaksin-covid-19/

Tambahnya, setakat ini, terdapat enam produk vaksin Covid-19 yang telah selesai dinilai oleh NPRA dalam masa yang ditetapkan dan telah mendapat kelulusan pendaftaran bersyarat daripada PBKD.

Katanya, pihak NPRA juga sedang menilai BEBERAPA PERMOHONAN BAHARU bersyarat vaksin-vaksin Covid-19 pada masa ini.

“Permohonan ini juga akan disegerakan dengan kaedah yang sama. NPRA sememangnya sentiasa terbuka menerima pandangan pelbagai pihak,” katanya

Source: https://www.kosmo.com.my/2021/05/25/npra-nafi-lewat-lulus-produk-vaksin-covid-19/

The price of Covid-19 Vaccines (updated 26 May 2021)

1. Pfizer-BioNTech - $19.50 per dose for first 100 million doses
2. Moderna - $25-$37 per dose
3. AstraZeneca-University of Oxford - $2.15 (U.S.) in the EU; $3-4 (U.S.) in the UK and U.S.; $5.25 (U.S.) in South Africa
4. Johnson & Johnson - $10 per dose
5. Russia’s Sputnik V Vaccine - $10 per dose
6. Sinovac Biotech - US$29.75 per dose in China ** edited: $5-$38 per dose in ASEAN
7. Novavax - $16 in the US
8. CanSino Biologics - Unknown
9. Bharat Biotech - Rp 150 or about $2 (U.S.), although that appears to be the low-end of the open-market price in India

*** to add:
10. Sinopharm - $15 per dose in Sri Lanka and $10 in Bangladesh

Source: https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v/

According to the Daily Mirror, Sri Lanka is paying $15 per dose for the Sinopharm vaccine, which is USD 5 higher than what Bangladesh paid.

Sekarang ni technical out, fundamental out. Tinggal Hope analysis saja
------------------------
Perniagaan Covid-19 vaksin bukan fundamental bagi syarikat. Ianya sekadar BONUS.
Secara fundamentalnya perniagaan asalnya berkaitan bamboo floring dan berkaitan masih berjalan dan dalam usaha untunk dikembangkan lagi. Selain itu terdapat beberapa projek lain dirangka termasuk yang terbaharu melibatkan pembelian 51% syarikat berasaskan perniagaan pembekal bahan binaan yang agak kukuh dari segi perniagaannya. Ini antaranya.

Dari segi teknikal pula, memang harga saham akan jatuh dan naik mengikut keadaan pasaran saham secara keseluruhan dan keadaan berkaitan dengan kaunter itu sendiri secara spesifik. Kalau harganya dalam trend mnurun pun akan sampai masa supportnya, dari dari situ mungkin akan beralih trendnya, juga mengikut keadaan pasaran saham secara keseluruhan dan keadaan yang berlaku atau mungkin akan berlaku di dalam kaunter itu sendiri.

Jangka masa pendek ini, saya tertarik untuk melihat bagaimana respon terhadap harga saham Kanger sebelum RI dilaksanakan nanti.

Have to wait on 8th??? The day of the new shares listed??

Meanwhile, referring to social media reports, the Chinese Embassy of Sri Lanka said the Bangladesh has not yet finalized their procurement agreement including pricing.

“We checked with Chinese Embassy in Dhaka as well as #Sinopharm group. Bangladesh Health Minister has clarified last week that their procurement agreement including pricing is not finalized yet. The fake news on social media has already disturbed their ongoing negotiation,” the Chinese Embassy said.

China to supply 1 billion vaccine doses overseas by year end - Global Times

Source: https://www.theedgemarkets.com/article/china-supply-1-billion-vaccine-doses-overseas-year-end-global-times#.YLoaa4Qn1UM.telegram

My remarks:
1. Wuhan Institute of Biological Products saya rasa satu lagi vaksin oleh Sinopharm, Sinopharm / WIBP2. WIBP tu ialah Wuhan Institute of Biological Products.

2. Yang dah lulus 7 Mei tu, Vaksin Sinopharm / BIBP1 vaccine was developed through a collaboration between the Chinese Center for Disease Control and Prevention (CDC) and the Beijing Institute of Biological Products (BIBP)/China National Biotec Group Company Limited (CNBG).

3. Kedua-duanya melibatkan CNBG yang dikaitkan dengan perjanjian distribution dengan Kanger

China to supply 1 billion vaccine doses overseas by year end - Global Times

Source: https://www.theedgemarkets.com/article/china-supply-1-billion-vaccine-doses-overseas-year-end-global-times#.YLoaa4Qn1UM.telegram

My remarks:
1. Wuhan Institute of Biological Products saya rasa satu lagi vaksin oleh Sinopharm, Sinopharm / WIBP2. WIBP tu ialah Wuhan Institute of Biological Products.

2. Yang dah lulus 7 Mei tu, Vaksin Sinopharm / BIBP1 vaccine was developed through a collaboration between the Chinese Center for Disease Control and Prevention (CDC) and the Beijing Institute of Biological Products (BIBP)/China National Biotec Group Company Limited (CNBG).

3. Kedua-duanya melibatkan CNBG yang dikaitkan dengan perjanjian distribution dengan Kanger

SHAH ALAM - Tempoh penilaian permohonan lengkap bagi pendaftaran bersyarat untuk vaksin Covid-19 telah dipendekkan daripada 245 hari kepada 120 hari bekerja.

@Noobie. As stated in the company's report to Bursa and media, it should be as stated, It is Hunan Changde Medical Equipment Co., Ltd

@Noobie123.
Separate agreement on type of product to be signed between Sinopharm and Kanger. Where is it?
--------------------
I can't get any upadated info about this.
May be they not yet sign it.

But I think the signing detail about it not so material because the major agreement deal has been signed and announced @ KLSE.

@Noobie123.

Question 2. Is Sinopharm Changde Hunan is authorised for overseas export of Sinopharm. Are you sure Kanger signed with the right party? What type of operations does Changde Hunan really do?
---------------------

I am not sure about Sinopharm Hunan Changde Medical Co. Ltd. authorisation to export of Sinopharm vaccine.

But, the existence of this company and its relation with Sinopharm Group of company can be verified as follows:

Sinopharm, Hunan Changde Medical is a company incorporated in the People Republic of China (“PRC”) with a business address at No. 22, 3rd Floor, Zone A, Tower 2, Long Mei Street, Changde Economic and Technological Development Changde, Hunan Province, PRC. Sinopharm Hunan Changde is principally engaged in sale of medical supplies and equipment, and is part of Sinopharm Group, which is a large Chinese state-owned healthcare group.

(Note: The Sinopharm Group Hunan Changde Medical Co. Ltd. existence can be checked @ this web link: http://www.info-clipper.com/en/company/china/sinopharm-holding-hunan-changde-medical-equipment-co-ltd.cnd9657ed.html ).

And also, there is an evidence base on the report that,
"Kanger will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp Sinopharm) for trial purposes"

(Note: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes )


My conclusion is Sinopharm Hunan Changde Medical Co. Ltd. is exist and Kanger suppose to import the Sinopharm vaccine via Sinopharm Hunan Changde Medical Co. Ltd.'s dealearship.

Question 1. Sinopharm got 2 types of vaccine Wuhan & Bejing. Which vaccine are we talking about. WHO approved which vaccine? Did Kanger sign for the approved type of vaccine?
------------------------

Kanger had entered a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.

Additional information related:

1. China National Biotec Group (CNBG), is a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM).

2. Sinopharm vaccine Sinopharm / BIBP1 or SARS-CoV-2 - BIBP1 was developed through a collaboration between the Chinese Center for Disease Control and Prevention (CDC) and the Beijing Institute of Biological Products (BIBP)/China National Biotec Group Company Limited (CNBG).

3. CNBG is also developing another vaccine, Sinopharm / WIBP1 or SARS-CoV-2 - WIBP1.

4. The Sinopharm / BIBP1 vaccine has been approved by WHO on 7 May 2021, where as Sinopharm / WIBP1 is still under its assessment process by WHO.


As a conclusion, BOTH OF THE VACCINES ARE RELATED TO CNBC, AND CAN BE DISTRIBUTED BY CANGDE MEDICAL CO. LTD. But I thinks its better for Kanger to focus more on currently approve vaccine, it is Sinopharm / BIBP1.

Noobie123. I look up and look down...still cannot find the word "SOLE DISTRIBUTOR. "

-----------------------
Yes there is a discrepancy there:
1. Based on announcent @ KLSE.
Just stated as distributor

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107

2. Based on MSN news report.
Under the agreement, Sinopharm Group has appointed KIB as the sole distributor for the
vaccines, medical devices and products in Malaysia.

Source: https://www.msn.com/en-my/news/national/kanger-sinopharm-inks-agreement-for-covid-19-vaccine-distribution-in-malaysia/ar-BB19x0Lr